Inhibition of ascites tumor growth in vivo by sTie-2 is potentiated by a combinatorial therapy with sFLT-1

Journal of Gene Medicine

Volumn 12, Issue 12, 2010, Pages 968-980

  D'Souza, Saritha Sandra ^a   Gururaj, Anupama E ^b   Raj, Harsha M ^a   Rössler, Jochen ^c   Salimath, Bharathi P ^a  

^a UNIVERSITY OF MYSORE   (India)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Angiogenesis; Angiopoietins; Ascites; Recombinant sTie 2; SFLT 1

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN 2; CD31 ANTIGEN; MESSENGER RNA; RECOMBINANT PROTEIN; RECOMBINANT SFLT1; RECOMBINANT STIE 2; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; ASCITES TUMOR; BACULOVIRUS EXPRESSION SYSTEM; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER INVASION; CANCER SIZE; CELL COUNT; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; GENETIC TRANSFECTION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PERITONEUM; PRIORITY JOURNAL; TREATMENT RESPONSE; WOUND HEALING;

ANGIOPOIETIN-2; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, EHRLICH TUMOR; CELL PROLIFERATION; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, TIE-2; SOLUBILITY; TRANSFECTION; TRANSPLANTS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 78650028812     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1520     Document Type: Article

References (43)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
2. Ramachandra S, D'Souza SS, Gururaj AE, Shaila MS, Salimath BP. Paracrine action of sFLT-1 secreted by stably transfected Ehrlich ascites tumor cells and therapy using sFLT-1 inhibits ascites tumor growth in vivo. J Gene Med 2009; 11: 422-434.
3. Zogakis TG, Libutti SK. General aspects of antiangiogenesis and cancer therapy. Expert Opin Biol Ther 2001; 1: 253-275.
4. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434.
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
6. Millauer B, Longhi MP, Plate KH, et al. Dominant negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 1996; 56: 1615-1620.
7. Goldman CK, Kendall RL, Cabrera G, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 1998; 95: 8795-8800.
8. Partanen J, Dumont DJ. Functions of Tie1 and Tie2 receptor tyrosine kinases in vascular development. Curr Top Microbiol Immunol 1999; 237: 159-172.
9. Dumont DJ, Gradwohl GJ, Fong GH, Auerbach R, Breitman ML. The endothelial-specific receptor tyrosine kinase, tek, is a member of a new subfamily of receptors. Oncogene 1993; 8: 1293-1302.
10. Iwama A, Hamaguchi I, Hashiyama M, Murayama Y, Yasunaga K, Suda T. Molecular cloning and characterization of mouse TIE and TEK receptor tyrosine kinase genes and their expression in hematopoietic stem cells. Biochem Biophys Res Commun 1993; 195: 301-309.
11. Schnurch H, Risau W. Expression of tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage. Development 1993; 119: 957-968.
12. Dumont DJ, Fong GH, Puri MC, Gradwohl G, Alitalo K, Breitman ML. Vascularization of the mouse embryo: a study of flk-1, tek, tie, and vascular endothelial growth factor expression during development. Dev Dyn 1995; 203: 80-92.
13. Rodewald HR, Sato TN. Tie1, a receptor tyrosine kinase essential for vascular endothelial cell integrity, is not critical for the development of hematopoietic cells. Oncogene 1996; 12: 397-404.
14. Sato TN, Tozawa Y, Deutsch U, et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995; 376: 70-74.
15. Marron MB, Singh H, Tahir TA, et al. Regulated proteolytic processing of Tie1 modulates ligand responsiveness of the receptor-tyrosine kinase Tie2. J Biol Chem 2007; 282: 30509-30517.
16. Brindle NP, Saharinen P, Alitalo K. Signaling and functions of angiopoietin-1 in vascular protection. Circ Res 2006; 98: 1014-1023.
17. Saharinen P, Eklund L, Miettinen J, et al. Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat Cell Biol 2008; 10: 527-537.
18. Saharinen P, Kerkela K, Ekman N, et al. Multiple angiopoietin recombinant proteins activate the Tie1 receptor tyrosine kinase and promote its interaction with Tie2. J Cell Biol 2005; 169: 239-243.
19. Yuan HT, Venkatesha S, Chan B, et al. Activation of the orphan endothelial receptor Tie1 modifies Tie2-mediated intracellular signaling and cell survival. FASEB J 2007; 21: 3171-3183.
20. Eklund L, Olsen BR. Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp Cell Res 2006; 312: 630-641.
21. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277: 55-60.
22. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997; 277: 48-50.
23. Davis S, Yancopoulos GD. The angiopoietins: ying and yang in angiogenesis. Curr Top Microbiol Immunol 1999; 237: 173-185.
24. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999; 18: 5356-5362.
25. Thurston G, Rudge JS, Ioffe E, et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000; 6: 460-463.
26. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-248.
27. Wong AL, Haroon ZA, Werner S, Dewhirst MW, Greenberg CS, Peters KG. Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res 1997; 81: 567-574.
28. Peters KG, Coogan A, Berry D, et al. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer 1998; 77: 51-56.
29. Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 1998; 153: 1459-1466.
30. Lin P, Polverini P, Dewhirst M, Shan S, Rao PS, Peters K. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J Clin Invest 1997; 100: 2072-2078.
31. Lin P, Buxton JA, Acheson A, et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci USA 1998; 95: 8829-8834.
32. Siemeister G, Schirner M, Weindel K, et al. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. Cancer Res 1999; 59: 3185-3191.
33. Stratmann A, Acker T, Burger AM, Amann K, Risau W, Plate KH. Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants. Int J Cancer 2001; 91: 273-282.
34. Hayes AJ, Huang WQ, Mallah J, Yang D, Lippman ME, Li LY. Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells. Microvasc Res 1999; 58: 224-237.
35. White RR, Shan S, Rusconi CP, et al. Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin. Proc Natl Acad Sci USA 2003; 100: 5028-5033.
36. Niu Q, Perruzzi C, Voskas D, Lawler J, Dumont DJ, Benjamin LE. Inhibition of Tie-2 signaling induces endothelial cell apoptosis, decreases Akt signaling, and induces endothelial cell expression of the endogenous anti-angiogenic molecule, thrombospondin-1. Cancer Biol Ther 2004; 3: 402-405.
37. Tournaire R, Simon M-P, le Noble F, Eichmann A, England P, Pouyssegur J. A short synthetic peptide inhibits signal transduction, migration and angiogenesis mediated by Tie2 receptor. EMBO Reports 2004; 5: 1-6.
38. Popkov M, Jendreyko N, McGavern DB, Rader C, Barbas CF. Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody. Cancer Research 2005; 65: 972-981.
39. Shivakumar S, Prabhakar BT, Jayashree K, Salimath BP. Evaluation of serum vascular endothelial growth factor (VEGF) and microvessel density (MVD) as prognostic indicatorsin carcinoma breast. J Cancer Res Clin Oncol 2009; 135: 627-636.
40. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 456-481.
41. Zhang D, Li B, Shi J, et al. Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein. Cancer Res 2010; 70: 2495-2503.
42. Rosenfeld ME, Wang M, Siegal GP, et al. Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumour reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma. J Mol Med 1996; 74: 455-462.
43. Rancourt C, Rogers BE, Sosnowski BA, et al. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin Cancer Res 1998; 4: 2455-2461.